News ArticleNeuland Laboratories Reports ₹26,682.52 Lakhs Profit Before Tax for H1 FY2026 and Approves ₹47.1 Crore Land Acquisition for Capacity Expansion
Unaudited financial results for quarter and half year ended September 30, 2026, and ₹47.1 crore investment in land parcel at Domadugu Village, Telangana funded through internal accruals
Neuland Laboratories Limited announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a profit before tax of ₹26,682.52 lakhs for H1 FY2026. The company also approved a ₹47.1 crore capital expenditure for land acquisition aimed at future capacity expansion in Telangana, funded through internal accruals.
Neuland Laboratories Limited
Financial Results
Neuland Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, reporting a profit before tax of ₹26,682.52 lakhs for the half year. Additionally, the Board approved a capital expenditure of ₹47.1 crores for acquiring land in Telangana to support future capacity expansion, financed through internal resources.
The company reported total income of ₹1,10,722.10 lakhs and total expenses of ₹84,039.58 lakhs for the half year ended September 30, 2026, leading to a profit before tax of ₹26,682.52 lakhs.
The Board approved the acquisition of a land parcel measuring 6 acres at Domadugu Village, Sangareddy District, Telangana, including related expenditures totaling approximately ₹47.1 crores including GST.
The investment for the land acquisition will be funded through internal accruals, indicating no external borrowing for this expenditure.
Details regarding current capacity or utilization are not applicable since this acquisition is intended for future expansion.
The financial results cover both standalone and consolidated figures as reviewed by the statutory auditors with limited review reports attached.
Highlights
- Profit before tax of ₹26,682.52 lakhs for half year ended September 30, 2026.
- Total income for half year amounted to ₹1,10,722.10 lakhs.
- Board approved capital expenditure of ₹47.1 crores for land acquisition in Telangana.
- Land parcel size is 6 acres located at Domadugu Village, Sangareddy District.
- Funding of capital expenditure through internal accruals with no planned external financing.
- Financial results for Q2 and H1 FY2026 are unaudited but reviewed by statutory auditors.
Key Data Snapshot
What happened
- Neuland Laboratories announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- The Board approved a capital expenditure of ₹47.1 crores for acquisition of a land parcel measuring 6 acres in Telangana.
- This investment is intended for future capacity expansion.
- The acquisition will be funded through internal accruals without external borrowings.
Key details
- The profit before tax for the half year ended September 30, 2026 was ₹26,682.52 lakhs.
- Total income stood at ₹1,10,722.10 lakhs, while total expenses were ₹84,039.58 lakhs for the half year.
- The land parcel is located at Domadugu Village, Sangareddy District in Telangana.
- Existing capacity and capacity utilization details are not applicable for this acquisition as it is intended for future expansion.
Regulatory and governance context
- The financial results were reviewed by the statutory auditors with limited review reports appended.
- The disclosures were made under Regulation 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
- The Board meeting was held on November 3, 2026 and commenced at 9:30 a.m. and concluded at 3:34 p.m.
Highlights
- Profit before tax of ₹26,682.52 lakhs for half year ended September 30, 2026.
- Total income for half year amounted to ₹1,10,722.10 lakhs.
- Board approved capital expenditure of ₹47.1 crores for land acquisition in Telangana.
- Land parcel size is 6 acres located at Domadugu Village, Sangareddy District.
- Funding of capital expenditure through internal accruals with no planned external financing.
- Financial results for Q2 and H1 FY2026 are unaudited but reviewed by statutory auditors.
Disclosures
- SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 - Regulations 30 and 33
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Biocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
Read Full Story
Zydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
